$CTIX Cellceutix’s Phase 2 Drug Candidate Brilacidin Emerging as a Potential Novel Non-Biologic Therapy in Treating Inflammatory Bowel Disease
Brilacidin
Study to help guide Cellceutix in continued development of Brilacidin, including planned foam and oral formulations for hard-to-treat chronic conditions like Ulcerative Colitis and Crohn’s Disease
Expecting Prurisol P2b interim data in April though they may squeeze it out end of March. Halfway point just passed depending on how many patients they had from the get go.
"Perfection is not attainable, but if we chase perfection we can catch excellence." Vince Lombardi Do your research! Play the TA. All posts are my opinion.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.